{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T13:27:37Z","timestamp":1789133257543,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T00:00:00Z","timestamp":1695254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T00:00:00Z","timestamp":1695254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National High Level Hospital Clinical Research Funding","award":["2022-NHLHCRF-YS-02"],"award-info":[{"award-number":["2022-NHLHCRF-YS-02"]}]},{"name":"Elite Medical Professionals Project of China-Japan Friendship Hospital","award":["NO.ZRJY2023-GG02"],"award-info":[{"award-number":["NO.ZRJY2023-GG02"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Macrophage activation syndrome (MAS) is a severe and life-threatening syndrome associated with autoimmune diseases. The coexistence of MAS and juvenile dermatomyositis (JDM) is not well reported. This report describes a case of JDM with MAS and summarizes the clinical characteristics and prognosis of MAS in patients with JDM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>The patient was a 15-year-old female with JDM, presenting with heliotrope rash, muscle weakness, increased muscle enzyme, anti-nuclear matrix protein 2 (NXP2) antibody, and muscle biopsy consistent with JDM. The patient developed fever, cytopenia, and hyperferritinemia three months after the first manifestations. Hemophagocytosis was found in the bone marrow. The final diagnosis was JDM combined with MAS. Despite intensive treatment, the patient died of MAS. By reviewing the literature, we found 17 similar cases. Together with the present case, 18 patients were identified, the median age of disease onset was 13.5 years, and male to female ratio was 1.25: 1. Nine out of 16 (56.3%) patients were complicated with interstitial lung disease (ILD). The median time interval between JDM onset and MAS diagnosis was 9 weeks. At the onset of MAS, all (100%) patients had elevated levels of ferritin and serum liver enzymes. Among 18 patients, 14 (77.8%) had fever, 14\/17 (82.4%) had cytopenia, 11\/11 (100%) had hepatosplenomegaly, and 13\/14 (92.9%) had hemophagocytosis. Five (27.8%) patients showed central nervous system (CNS) involvement. The mortality of MAS rate of in patients with JDM was 16.7%, despite various treatment methods.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>. The coexistence of JDM and MAS is underestimated with increased mortality. Hepatosplenomegaly and increased serum levels of ferritin in patients with JDM should raise clinical suspicion for MAS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12969-023-00893-w","type":"journal-article","created":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T08:01:51Z","timestamp":1695283311000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Macrophage activation syndrome in juvenile dermatomyositis: a case report and a comprehensive review of the literature"],"prefix":"10.1186","volume":"21","author":[{"given":"Yong","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyan","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3674-9307","authenticated-orcid":false,"given":"Yongpeng","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,21]]},"reference":[{"issue":"3","key":"893_CR1","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1080\/14397595.2020.1718866","volume":"30","author":"I Kobayashi","year":"2020","unstructured":"Kobayashi I, Akioka S, Kobayashi N, Iwata N, Takezaki S, Nakaseko H, et al. Clinical practice guidance for juvenile dermatomyositis (JDM) 2018-Update. Mod Rheumatol. 2020;30(3):411\u201323.","journal-title":"Mod Rheumatol"},{"issue":"8","key":"893_CR2","doi-asserted-by":"publisher","first-page":"e309","DOI":"10.3928\/19382359-20170717-01","volume":"46","author":"YM Esteban","year":"2017","unstructured":"Esteban YM, de Jong JLO, Tesher MS. An overview of Hemophagocytic Lymphohistiocytosis. Pediatr Ann. 2017;46(8):e309\u201313.","journal-title":"Pediatr Ann"},{"issue":"3","key":"893_CR3","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/s12098-015-1877-1","volume":"83","author":"ES Sen","year":"2016","unstructured":"Sen ES, Clarke SL, Ramanan AV. Macrophage activation syndrome. Indian J Pediatr. 2016;83(3):248\u201353.","journal-title":"Indian J Pediatr"},{"issue":"2","key":"893_CR4","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/pbc.21039","volume":"48","author":"JI Henter","year":"2007","unstructured":"Henter JI, Horne A, Aric\u00f3 M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124\u201331.","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"893_CR5","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1111\/j.1651-2227.2000.tb00351.x","volume":"89","author":"I Kobayashi","year":"2000","unstructured":"Kobayashi I, Yamada M, Kawamura N, Kobayashi R, Okano M, Kobayashi K. Platelet-specific hemophagocytosis in a patient with juvenile dermatomyositis. Acta Paediatr. 2000;89(5):617\u20139.","journal-title":"Acta Paediatr"},{"issue":"5","key":"893_CR6","first-page":"1014","volume":"31","author":"G Sterba","year":"2004","unstructured":"Sterba G, Rodriguez C, Sifontes S, Vigilanza P. Macrophage activation syndrome due to methotrexate in a 12-year-old boy with dermatomyositis. J Rheumatol. 2004;31(5):1014\u20135.","journal-title":"J Rheumatol"},{"issue":"1","key":"893_CR7","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1080\/03009740510018642","volume":"35","author":"I Kobayashi","year":"2006","unstructured":"Kobayashi I, Kawamura N, Okano M, Sageshima S, Nakayama T, Ohyu J, et al. Thrombocytopaenia in juvenile dermatomyositis. Scand J Rheumatol. 2006;35(1):79\u201380.","journal-title":"Scand J Rheumatol"},{"issue":"9","key":"893_CR8","first-page":"1838","volume":"35","author":"N Yajima","year":"2008","unstructured":"Yajima N, Wakabayashi K, Odai T, Isozaki T, Matsunawa M, Miwa Y, et al. Clinical features of hemophagocytic syndrome in patients with dermatomyositis. J Rheumatol. 2008;35(9):1838\u201341.","journal-title":"J Rheumatol"},{"issue":"1","key":"893_CR9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.anpedi.2011.12.011","volume":"77","author":"BR Bustos","year":"2012","unstructured":"Bustos BR, Carrasco AC, Toledo RC. Plasmapheresis for macrophage activation syndrome and multiorgan failure as first presentation of juvenile dermatomyositis. An Pediatr (Barc). 2012;77(1):47\u201350.","journal-title":"An Pediatr (Barc)"},{"issue":"9","key":"893_CR10","first-page":"4142","volume":"7","author":"W Qianhan","year":"2013","unstructured":"Qianhan W, Qihua F, Jiang C, et al. A case of juvenile dermatomyositis complicated with macrophage activation syndrome. Chin J Clinicians (Electronic Edition). 2013;7(9):4142\u20133.","journal-title":"Chin J Clinicians (Electronic Edition)"},{"issue":"2","key":"893_CR11","doi-asserted-by":"publisher","first-page":"386","DOI":"10.3109\/s10165-012-0661-6","volume":"23","author":"H Yamashita","year":"2013","unstructured":"Yamashita H, Matsuki Y, Shimizu A, Mochizuki M, Takahashi Y, Kano T, et al. Hemophagocytic lymphohistiocytosis complicated by central nervous system lesions in a patient with dermatomyositis: a case presentation and literature review. Mod Rheumatol. 2013;23(2):386\u201392.","journal-title":"Mod Rheumatol"},{"issue":"2","key":"893_CR12","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3109\/03009742.2013.863968","volume":"43","author":"V Lilleby","year":"2014","unstructured":"Lilleby V, Haydon J, Sanner H, Krossness BK, Ringstad G, Flat\u00f8 B. Severe macrophage activation syndrome and central nervous system involvement in juvenile dermatomyositis. Scand J Rheumatol. 2014;43(2):171\u20133.","journal-title":"Scand J Rheumatol"},{"issue":"9","key":"893_CR13","first-page":"649","volume":"18","author":"Y Bin","year":"2014","unstructured":"Bin Y, Xiaoxuan S, Chunxia Z, Hong Y, Li M, Huiqiong Z. Dermatomyositis complicated with hemophagocytic syndrome with normal peripheral blood system: a case report. Chin J Rheumatol. 2014;18(9):649\u201350.","journal-title":"Chin J Rheumatol"},{"issue":"11","key":"893_CR14","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.autrev.2014.05.009","volume":"13","author":"D Poddighe","year":"2014","unstructured":"Poddighe D, Cavagna L, Brazzelli V, Bruni P, Marseglia GL. A hyper-ferritinemia syndrome evolving in recurrent macrophage activation syndrome, as an onset of amyopathic juvenile dermatomyositis: a challenging clinical case in light of the current diagnostic criteria. Autoimmun Rev. 2014;13(11):1142\u20138.","journal-title":"Autoimmun Rev"},{"issue":"4","key":"893_CR15","doi-asserted-by":"publisher","first-page":"218","DOI":"10.4274\/jpr.53825","volume":"1","author":"\u015e\u015e \u00d6nen","year":"2014","unstructured":"\u00d6nen \u015e\u015e, \u00dcmit Z, Sivi\u015f Z, Evin F, Kasap M, Ya\u015far BE, et al. Juvenile dermatomyositis with a rare and severe complication: macrophage activation syndrome. J Pediatr Res. 2014;1(4):218\u201321.","journal-title":"J Pediatr Res"},{"key":"893_CR16","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12969-015-0048-2","volume":"13","author":"H Wakiguchi","year":"2015","unstructured":"Wakiguchi H, Hasegawa S, Hirano R, Kaneyasu H, WakabayashiTakahara M, Ohga S. Successful control of juvenile dermatomyositis-associated macrophage activation syndrome and interstitial pneumonia: distinct kinetics of interleukin-6 and \u2013 18 levels. Pediatr Rheumatol Online J. 2015;13:49.","journal-title":"Pediatr Rheumatol Online J"},{"key":"893_CR17","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s13256-016-0986-4","volume":"10","author":"S Teshigawara","year":"2016","unstructured":"Teshigawara S, Katada Y, Maeda Y, Yoshimura M, Kudo-Tanaka E, Tsuji S, et al. Hemophagocytic lymphohistiocytosis with leukoencephalopathy in a patient with dermatomyositis accompanied with peripheral T-cell lymphoma: a case report. J Med Case Rep. 2016;10:212.","journal-title":"J Med Case Rep"},{"issue":"4","key":"893_CR18","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1093\/pch\/pxx209","volume":"23","author":"R Deschamps","year":"2018","unstructured":"Deschamps R, Couture J, Hadjinicolaou A, LeBlanc CMA. A 17-year-old girl with facial edema and weakness. Paediatr Child Health. 2018;23(4):241\u20134.","journal-title":"Paediatr Child Health"},{"issue":"1","key":"893_CR19","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12969-022-00675-w","volume":"20","author":"JA Stewart","year":"2022","unstructured":"Stewart JA, Price T, Moser S, Mullikin D, Bryan A. Progressive, refractory macrophage activation syndrome as the initial presentation of anti-MDA5 antibody positive juvenile dermatomyositis: a case report and literature review. Pediatr Rheumatol Online J. 2022;20(1):16.","journal-title":"Pediatr Rheumatol Online J"},{"key":"893_CR20","doi-asserted-by":"crossref","unstructured":"Mouri M, Kanamori T, Tanaka E, Hiratoko K, Okubo M, Inoue M et al. Hepatic veno-occlusive disease accompanied by thrombotic microangiopathy developing during treatment of juvenile dermatomyositis and macrophage activation syndrome: a case report. Mod Rheumatol Case Rep. 2022; rxac086.","DOI":"10.1093\/mrcr\/rxac086"},{"issue":"9","key":"893_CR21","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s13312-022-2606-2","volume":"59","author":"H Jagwani","year":"2022","unstructured":"Jagwani H, Mondal A, Pal P. Juvenile Dermatomyositis with macrophage activation and severe Encephalopathy. Indian Pediatr. 2022;59(9):725\u20136.","journal-title":"Indian Pediatr"},{"key":"893_CR22","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1093\/rheumatology\/keu259","volume":"53","author":"SL Tansley","year":"2014","unstructured":"Tansley SL, Betteridge ZE, Shaddick G, Gunawardena H, Arnold K, Wedderburn LR, et al. Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset. Rheumatology (Oxford). 2014;53:2204\u20138.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"893_CR23","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.berh.2017.12.003","volume":"31","author":"Q Wu","year":"2017","unstructured":"Wu Q, Wedderburn LR, McCann LJ. Juvenile dermatomyositis: latest advances. Best Pract Res Clin Rheumatol. 2017;31(4):535\u201357.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"6","key":"893_CR24","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1002\/art.24547","volume":"60","author":"H Gunawardena","year":"2009","unstructured":"Gunawardena H, Wedderburn LR, Chinoy H, Betteridge ZE, North J, Ollier WER, et al. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum. 2009;60(6):1807\u201314.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"893_CR25","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s10067-013-2227-1","volume":"32","author":"S Vilaiyuk","year":"2013","unstructured":"Vilaiyuk S, Sirachainan N, Wanitkun S, Pirojsakul K, Vaewpanich J. Recurrent macrophage activation syndrome as the primary manifestation in systemic lupus erythematosus and the benefit of serial ferritin measurements: a case-based review. Clin Rheumatol. 2013;32(6):899\u2013904.","journal-title":"Clin Rheumatol"},{"key":"893_CR26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12969-015-0055-3","volume":"13","author":"V Boom","year":"2015","unstructured":"Boom V, Anton J, Lahdenne P, Quartier P, Ravelli A, Wulffraat NM, et al. Evidenced-based diagnosis and treatment of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2015;13:55.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"4","key":"893_CR27","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.semarthrit.2014.07.007","volume":"44","author":"W Wang","year":"2015","unstructured":"Wang W, Gong F, Zhu W, Fu S, Zhang Q. Macrophage activation syndrome in Kawasaki disease: more common than we thought? Semin Arthritis Rheum. 2015;44(4):405\u201310.","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"893_CR28","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s00296-019-04442-1","volume":"40","author":"D Poddighe","year":"2020","unstructured":"Poddighe D, Dauyey K. Macrophage activation syndrome in juvenile dermatomyositis: a systematic review. Rheumatol Int. 2020;40(5):695\u2013702.","journal-title":"Rheumatol Int"},{"issue":"10","key":"893_CR29","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1002\/ppul.22742","volume":"48","author":"G Pouessel","year":"2013","unstructured":"Pouessel G, Deschildre A, Le Bourgeois M, Cuisset JM, Catteau B, Karila C, et al. The lung is involved in juvenile dermatomyositis. Pediatr Pulmonol. 2013;48(10):1016\u201325.","journal-title":"Pediatr Pulmonol"},{"key":"893_CR30","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1097\/MPH.0b013e3181923cb4","volume":"31","author":"AA Gupta","year":"2009","unstructured":"Gupta AA, Tyrrell P, Valani R, Benseler S, Abdelhaleem M, Weitzman S. Experience with hemophagocytic lymphohistiocytosis\/macrophage activation syndrome at a single institution. J Pediatr Hematol Oncol. 2009;31:81\u20134.","journal-title":"J Pediatr Hematol Oncol"},{"key":"893_CR31","doi-asserted-by":"publisher","first-page":"204062232210981","DOI":"10.1177\/20406223221098128","volume":"13","author":"Y Ding","year":"2022","unstructured":"Ding Y, Ge Y. Anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis complicated with macrophage activation syndrome. Ther Adv Chronic Dis. 2022;13:20406223221098128.","journal-title":"Ther Adv Chronic Dis"},{"issue":"7","key":"893_CR32","doi-asserted-by":"publisher","first-page":"947","DOI":"10.3899\/jrheum.170997","volume":"45","author":"H Kawasumi","year":"2018","unstructured":"Kawasumi H, Katsumata Y, Nishino A, Hirahara S, Kawaguchi Y, Kuwana M, et al. Association of serum soluble CD163 with Polymyositis and Dermatomyositis, especially in Anti-MDA5 antibody-positive cases. J Rheumatol. 2018;45(7):947\u201355.","journal-title":"J Rheumatol"},{"issue":"1","key":"893_CR33","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.clim.2009.02.005","volume":"132","author":"A Coca","year":"2009","unstructured":"Coca A, Bundy KW, Marston B, Huggins J, Looney RJ. Macrophage activation syndrome: serological markers and treatment with anti-thymocyte globulin. Clin Immunol. 2009;132(1):10\u20138.","journal-title":"Clin Immunol"},{"issue":"6","key":"893_CR34","doi-asserted-by":"publisher","first-page":"979","DOI":"10.3899\/jrheum.141307","volume":"42","author":"QL Peng","year":"2015","unstructured":"Peng QL, Zhang YL, Shu XM, Yang HB, Zhang L, Chen F, et al. Elevated serum levels of Soluble CD163 in Polymyositis and Dermatomyositis: Associated with macrophage infiltration in muscle tissue. J Rheumatol. 2015;42(6):979\u201387.","journal-title":"J Rheumatol"},{"issue":"9","key":"893_CR35","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1093\/rheumatology\/kes102","volume":"51","author":"T Gono","year":"2012","unstructured":"Gono T, Sato S, Kawaguchi Y, Kuwana M, Hanaoka M, Katsumata Y, et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology (Oxford). 2012;51(9):1563\u201370.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"893_CR36","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00296-019-04255-2","volume":"39","author":"T Nagashima","year":"2019","unstructured":"Nagashima T, Kamata Y, Iwamoto M, Okazaki H, Fukushima N, Minota S. Liver dysfunction in anti-melanoma differentiation-associated gene 5 antibody-positive patients with dermatomyositis. Rheumatol Int. 2019;39(5):901\u20139.","journal-title":"Rheumatol Int"},{"issue":"4","key":"893_CR37","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1128\/CVI.00306-10","volume":"18","author":"MF Ibarra","year":"2011","unstructured":"Ibarra MF, Klein-Gitelman M, Morgan E, Proytcheva M, Sullivan C, Morgan G, et al. Serum neopterin levels as a diagnostic marker of hemophagocytic lymphohistiocytosis syndrome. Clin Vaccine Immunol. 2011;18(4):609\u201314.","journal-title":"Clin Vaccine Immunol"},{"issue":"1","key":"893_CR38","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/diagnostics12010008","volume":"12","author":"A Khojah","year":"2021","unstructured":"Khojah A, Morgan G, Pachman LM. Clues to Disease Activity in Juvenile Dermatomyositis: neopterin and other biomarkers. Diagnostics (Basel). 2021;12(1):8.","journal-title":"Diagnostics (Basel)"},{"key":"893_CR39","doi-asserted-by":"publisher","first-page":"635654","DOI":"10.3389\/fphar.2021.635654","volume":"12","author":"S Li","year":"2021","unstructured":"Li S, Li W, Jiang W, He L, Peng Q, Wang G, et al. The efficacy of Tocilizumab in the treatment of patients with Refractory Immune-Mediated necrotizing Myopathies: an open-label pilot study. Front Pharmacol. 2021;12:635654.","journal-title":"Front Pharmacol"},{"issue":"7","key":"893_CR40","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1007\/s00296-020-04590-9","volume":"40","author":"D Kishida","year":"2020","unstructured":"Kishida D, Sakaguchi N, Ueno KI, Ushiyama S, Ichikawa T, Yoshinaga T, et al. Macrophage activation syndrome in adult dermatomyositis: a case-based review. Rheumatol Int. 2020;40(7):1151\u201362.","journal-title":"Rheumatol Int"},{"issue":"2","key":"893_CR41","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/art.41103","volume":"72","author":"EM Eloseily","year":"2020","unstructured":"Eloseily EM, Weiser P, Crayne CB, Haines H, Mannion ML, Stoll ML, et al. Benefit of Anakinra in treating Pediatric secondary hemophagocytic lymphohistiocytosis. Arthritis Rheumatol. 2020;72(2):326\u201334.","journal-title":"Arthritis Rheumatol"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-023-00893-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-023-00893-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-023-00893-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T21:21:11Z","timestamp":1700342471000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-023-00893-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,21]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["893"],"URL":"https:\/\/doi.org\/10.1186\/s12969-023-00893-w","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,21]]},"assertion":[{"value":"22 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Research Ethical Committee of China-Japan Friendship Hospital accredited this case study. We also obtained informed consent from the parents of the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"We obtained written informed consent from the patient\u2019s legal guardian to publish this case report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that there is no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"106"}}